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ABSTRACT 
 
This descriptive study was designed to investigate if college students attending a 
midwestern university are aware of the clinical manifestations, treatments, and genetic 
counseling methods for sickle cell disease. This study was also devised to determine 
whether or not students, who are more likely to be genetically affected by sickle cell 
disease, are more or less aware of their sickle cell disease status.  Two hundred and fifty- 
nine (259) University of Illinois Urbana- Champaign (UIUC) students, 18 years and 
older, enrolled in one of the three following Community Health courses: Community 
Health Organizations (CHLH 210), Health Care Systems (CHLH 250), and Introduction 
to Medical Ethics (CHLH 260) were used as study participants. These 259 participants 
were assessed on their general knowledge of sickle cell disease (SCD).  Participants in 
this study were given a sickle cell disease questionnaire that consisted of 11 questions on 
sickle cell incidence, prevalence, origin, counseling methods, and knowledge of trait 
status. Frequency tables, cross-tabulations, and chi-square tests were used to evaluate the 
variations of existing SCD knowledge among students. Results illustrated that 
participants did have some general knowledge of sickle cell disease.  Study results 
showed a statistical difference in the response rates for males and females when surveyed 
on the life expectancy of sickle cell disease (p = .047). Other results showed no statistical 
differences in response rates between ethnicities group and age.   
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CHAPTER 1 
INTRODUCTION 
1.1 Background 
Sickle cell disease (SCD) is an inherited blood disorder caused by abnormal 
hemoglobin (Creary, Williamson, & Kulkarni, 2007).  Sickle cell disease limits the 
oxygenating role of hemoglobin, resulting in the damaging or the “sickling” of the red 
blood cells (Barakat, Schwartz, Simon, & Radcliffe, 2008).  This disorder affects all parts 
of the human body and differs widely among individuals (Bloom, 1995).  In 1910, Dr. 
James Herrick, a Chicago physician, was the first American to formally report and 
identify elongated, sickle-shaped hemoglobin in an anemic Grenadian student’s blood 
smear. Herrick coined the now familiar term “sickle cell” (Ogamdi, 1994).  The sickle-
shaped red blood cells described by Herrick caused several complications, including 
chronic anemia, vaso-occlusive pain episodes, ischemic organ damage, infections, small 
stature, and delayed puberty (Barakat et al., 2008). For many generations sickle cell 
disease has been a prevalent disorder in Africa.  Reports show that sickle cell disease was 
a well-known disorder in West Africa and that the West African natives had several local 
names for this disease before it was discovered in America (Reid & Rodgers, 2007).  
Sickle cell disease affects millions of people throughout the world, and it is found 
to be the most common blood disorder among families whose ancestors came from Sub-
Saharan Africa, South America, Cuba, Central America, Saudi Arabia, India, and the 
Mediterranean regions (Creary et al., 2007).  Studies indicate that approximately 1 in 12 
African-Americans are heterozygous for the disorder, and approximately 1 in 500 
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African-American newborns are diagnosed annually with SCD (Boyd, Watkins, Price, 
Fleming, & DeBaun, 2005). Also, the life expectancy for SCD has doubled since the 
1960s. Before that time, few patients lived to reach adulthood (Platt, Brambilla, Rosse, 
Milner, Castro, Steinberg, & Klug, 1994).  
It was not until the 1970s that this blood disorder began to capture public attention 
in the United States. Prior to that time, many researchers held numerous misconceptions 
about the nature and course of the disease.  Richard Nixon was the first president to make 
sickle cell disease a matter of national concern by signing the Sickle Cell Anemia Control 
Act of 1972 (Cerami, 1974). In 1971, President Nixon focused his health message to 
Congress on sickle cell disease, which at that time was a virtually unknown inherited 
blood disorder in the African-American community (Reid & Rodgers, 2007).  The 1972 
act set the foundation for funding toward sickle cell screenings, counseling programs, and 
the development and distribution of sickle cell anemia educational materials to the 
general public (Woolley & Gerhard, 1999). With the help of President Nixon, several 
sickle cell disease research organizations were created, such as the Sickle Cell Disease 
Association of America (SCDAA), which was established by Charles Whitten in 1972. 
The SCDAA was designed to improve the quality of life for patients and families with 
sickle cell disease (Reid & Rodgers, 2007).  
 After the 1970s, the public’s focus unfortunately shifted once again.  The new 
law, which first established sickle cell education, genetic screenings, and counseling, was 
stated to be “fraught with controversy” (Treadwell, McClough, & Vichinsky, 2006).  
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Even the African-American community, which has a higher probability of inheriting 
SCD, began to regard informed reproductive decision methods, such as screening and 
counseling, with trepidation and distrust (Treadwell et al., 2006). After President Nixon 
turned sickle cell disease into a national priority, legislators quickly began to pass laws 
that mandated premarital and pre-school screenings for sickle cell disease. The U.S Air 
Force began to deny airmen, who were diagnosed as carrying the sickle cell trait, 
occupational opportunities if they were applying to be pilots or co-pilots, and insurance 
companies even increased premiums for individuals with the trait (Reid & Rodgers, 
2007).  The American people began to view these new legislative policies as genocidal, 
and these policies were eventually overturned (Reid & Rodgers, 2007). 
 The lack of national concern for SCD created a barrier in health care. 
Complications due to the sickling of the red blood cells therefore continue to be a 
significant issue to patients and physicians in today’s medical world.  Physicians remain 
puzzled by the biological and clinical intricacies of SCD, and SCD researchers are trying 
to find a cure to reverse the “sickling effect” in the human body.  
1.2 Purpose  
 Sickle cell disease continues to be a global health problem that presents major 
challenges to our health care systems. The reviewed SCD literature expresses a dire need 
for more public education and awareness on SCD in the United States. In comparison 
with other chronic diseases and blood disorders, sickle cell disease remains one of the 
least understood and puzzling medical conditions by health care workers and the general 
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public, as well as the least funded blood disorder (Clarke & Clare, 1981).  Misleading 
descriptions of sickle cell disease, as a race-related disease during the past few decades, 
have significantly contributed to the rise in the public’s misunderstanding of sickle cell 
disease (Clarke & Clare, 1981).  
In addition, existing research on SCD focuses on the awareness of the disease 
among college students attending Historically Black Colleges and Universities (HBCUs) 
where the majority of participants are of African-American descent. Therefore, a paucity 
of information exists regarding the awareness among college students attending 
midwestern universities. This study therefore attempts to determine if college students 
attending a midwestern university are aware of the clinical manifestations, treatments, 
and genetic counseling methods for sickle cell disease. This study hopes to determine 
whether or not students, who are more likely to be genetically affected by this disease, 
are more or less aware of their SCD status. 
1.3 Research Questions 
This research study attempts to answer the following three questions by using a 
sickle cell disease questionnaire to survey college students on their existing knowledge of 
sickle cell disease.  
Research Question 1 
How knowledgeable are midwestern college students on background information 
regarding sickle cell disease? 
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 Research Question 2 
Do any significant differences exist in awareness between ethnic groups or groups 
of students who have a higher probability of inheriting sickle cell disease traits? 
Research Question 3 
Do any significant differences exist in awareness between gender groups? 
1.4 Definitions 
For the purpose of this literature review, these phrases, frequently referenced 
throughout the text, are defined as follows: 
 Genetic counseling: Communication process between health care provider and 
client that emphasizes and provides accurate and up-to-date information about a 
genetic disorder in a sensitive and supportive, non-directive manner (SCDAA, 
2005).  
 Hemoglobin: Chemical substance (an iron containing protein) of the red blood 
cell, which carries oxygen to the tissues, and gives the cell its red color (SCDAA, 
2005). 
 Hemoglobin A (HbA): Hemoglobin is composed of two alpha globins and two 
beta globins, normally produced by children and adults (Jones, 2008, p. 119). 
 Hemoglobin C trait (AC): Inheritance of one gene for the usual hemoglobin (A) 
and one gene for hemoglobin (C). A person who has the hemoglobin C Trait (AC) 
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is a carrier of the hemoglobin C gene, and is not affected by the gene (SCDAA, 
2005). 
 Hemoglobin C disease: A person has both HbS and HbC and is often referred to 
as “HbSC.” Hemoglobin C causes red blood cells to develop. Having just some 
hemoglobin C and normal hemoglobin, a person will not have any symptoms of 
anemia. However, if the sickle hemoglobin S is combined with the target cell, 
some mild to moderate anemia may occur (UMMC, 2010). 
  Hemoglobin E disease: Similar to sickle cell-C disease except that an element has 
been replaced in the hemoglobin molecule under certain conditions, such as 
exhaustion, hypoxia, severe infection, and/or iron deficiency (UMMC, 2010). 
 Hemoglobin S-beta-thalassemia: An inheritance of both the thalassemia and 
sickle cell genes. The disorder produces symptoms of moderate anemia and many 
of the same conditions associated with sickle cell disease, but to a milder degree 
(UMMC, 2010). 
 Sickle cell anemia (SS): An inherited disorder of the red blood cells in which the 
hemoglobin is different from the normal hemoglobin. This unusual hemoglobin 
results in the production of unusually shaped cells and is referred to as “HbSS.” It 
is the most common and severe form of the sickle cell variations (SCDAA, 2005).  
 Sickle cell disease (SCD): An inherited disorder of the red blood cells in which 
one gene is for sickle hemoglobin (S) and the other gene is for unusual 
hemoglobin such as S, C, Thal (SCDAA, 2005; UMMC, 2010). 
7 
 
 Sickle cell trait: A person carrying the defective gene, HbS, but also has some 
normal hemoglobin HbA. Persons with the sickle cell trait are usually without 
symptoms of the disease, but mild anemia may occur under intense, stressful 
conditions, exhaustion, hypoxia (low oxygen), and/or severe infection. The 
sickling of the defective hemoglobin may occur and result in some complications 
associated with sickle cell disease (UMMC, 2010). 
1.5 Assumptions 
The following two assumptions have been made: 1) The data are reliable and 
accurate measurements of a student’s awareness, and 2) each participant answered the 
questionnaire without coercion.  
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CHAPTER 2 
LITERATURE REVIEW 
Introduction 
  The review of literature is a comprehensive overview of sickle cell disease. The 
following review includes background information on sickle cell disease, as well as 
information on the following topics: complications, treatments, federal government 
initiatives to support and improve sickle cell disease awareness in the United States, 
newborn screening, genetic testing, the patient-physician medical relationship, and the 
perception of sickle cell disease among health care providers.  The primary goal of this 
review is to highlight the lack of extensive knowledge and awareness of sickle cell 
disease among sickle cell disease patients, providers, and the general public.  
2.1 Natural History/Natural Selection 
Historians believe that DNA mutations, which were responsible for the first 
versions of the sickle cell gene, originally arose in various African regions (see Figure 2-
1), including Cameroon, Central Africa Republic, Benin, and Senegal (Jones, 2008). 
Studies show that the Trans-Atlantic slave trade introduced the sickle cell gene into the 
Americas and the Caribbean islands (see Figure 2-1). African slaves, who carried the 
sickle cell trait, had the specific β-globin gene.  Popmpa (1996) showed that carriers, who 
had the sickle cell trait, had a heterozygote advantage of being resistant to malarial 
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infection. The Indo-European sickle mutation also originated in the Indus Valley 
Harappa. This particular mutation is found in Saudi Arabia, Oman, Bahrain, and Kuwait. 
 
Figure 2-1: Geographical distribution of the sickle gene (Stuart & Nagel, 2004). 
A British colonial medical officer, E. A. Beet, stationed in Zimbabwe in the 
1940s, first observed that blood from malaria patients, who carried the sickle cell trait, 
had fewer malarial parasites compared to blood from patients without the trait (Bloom, 
1995). However, in the 1950s, Anthony C. Allison developed his own hypothesis on the 
association of malaria and the sickle cell trait. By following up on Beet and a physician in 
Zaire during that time, Allison was able to hypothesize that the sickle cell trait offered 
protection against malaria. He believed that people with the sickle cell trait did not easily 
succumb to malaria as often as people without the trait (Bloom, 1995).  Some evidence 
against Allison’s hypothesis shows no difference in the concentration of blood-borne 
malarial parasites that exist in people with the sickle cell trait compared those without it 
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(Bloom, 1995). However, research shows that the sickle cell traits offer more protection 
against malaria to children than to adults, and adults are able to develop antibodies that 
can attack parasites in the immune system and increase their survival rate in malarial 
climates.  Compared with adults, young children are not able to produce antibodies to the 
malaria disease until their immune system is more mature (Bloom, 1995).  
2.2 Genetics 
Sickle cell disease is one of the many hemoglobin variants that cause mutations to 
alter amino acids in the hemoglobin molecule (Popma, 1996). Normal adult hemoglobin 
HbA is a heterogeneous mixture of approximately 90% Hb A, 2.5% Hb A2, 3.5% Hb 
Alc, and small quantities of fetal hemoglobin (Popma, 1996).  All normal hemoglobin 
molecules consist of four polypeptide chains in which two are globin β chains and α 
globin chains (Popma, 1996). Sickle cell disease occurs when the hemoglobin produced 
is HbS instead of HbA. Genetically, sickle cell disease occurs when valine replaces 
glutamic acid at position 6 of the β globin chain (Popma, 1996).  
 In the United States, three prevalent genotypes of sickle cell disease occur (see 
Table 1). The genotypes are abnormal hemoglobins designated by their mutations within 
the globin chain. Homozygous SCD, HbSS, or sickle cell anemia, is known as one of the 
more common types of sickle cell beta genes inherited by both parents (SCDAA, 2005). 
Sickle cell hemoglobin SC is known as one of the milder traits formed by one S-globin 
chain and one β-globin chain. This gene is found among West Africans (Bloom, 1995). 
Also, the Sβ°-thalassemia and HbSS are classified as being more severe compared with 
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other genotypes, and they are found among populations from the Mediterranean region 
(Bloom, 1995). 
2.3 Inheritance Patterns 
Sickle cell disease is a recessive gene if two parents have two copies of the 
Hb S gene.  Children born to parents with these genes (see Figure 2-2) will have 
sickle cell disease. 
 
 
 
 
 
Figure 2-2: Two parents with sickle cell disease (Bloom, 1995). 
2.3.1 One Parent has Sickle Cell Disease and Sickle Cell Trait 
Figure 2-3 shows that one parent has the sickle cell disease Hb S genes; therefore, 
all of that parent’s gametes will carry the Hb S gene. The other parent has one Hb S gene 
and one Hb A gene. The chances for that parent with both the Hb S gene and the Hb A 
gene transmitting either gene are equal, or 50/50 (Bloom, 1995).  All children born to 
S  S
S 
S  SS  SS 
SS 
 
SS
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these parents will have either sickle cell disease or sickle cell trait children with the 
chances being 50/50 for each (see Figure 2-3).  
  
 
 
 
 Figure 2-3: One parent has sickle cell disease and sickle cell trait (Bloom, 1995). 
2.3.2 One parent has sickle cell disease and the other parent carries normal genes 
Figure 2-4 illustrates that the Hb A gene is carried by the normal parent and the 
gametes from this parent will carry this particular gene, as well as the sickle cell disease 
parent carrying the Hb S gene (Bloom, 1995). All children conceived from these parents 
will inherit one normal and one sickle cell gene. All children will have the sickle cell 
trait. 
 
 
 
 
Figure 2-4: One parent has sickle cell disease and the other parent carries normal genes  
                   (Bloom, 1995). 
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2.3.3 Two parents has sickle cell trait 
 
This case (see Figure 2-5) illustrates that both parents have an equal chance of 
transmitting the two genes. If both parents have the sickle cell trait, they will have a 25% 
chance of having children with sickle cell disease, as well as a 50% chance of carrying 
the sickle cell trait (Bloom, 1995). Also, a slight 25% chance occurs of children with 
normal genes.  In this case, 50% of the time one parent will transmit an Hb S gene, and 
the other half of the time the other parent will transmit an HbA gene (Bloom, 1995).  
 
 
 
 
Figure 2-5: Two Parents has Sickle Cell Trait (Bloom, 1995). 
2.3.4 One parent has sickle cell trait and the other is normal 
All children from this couple (see Figure 2-6) will display the sickle cell trait or 
have normal genes because half of the gametes of the parent who carries the sickle cell 
trait will carry the Hb S gene, and the other half will carry the Hb A (Bloom,1995).  This 
combination will result in a 50/50 chance of producing a child with normal genes or 
inheriting sickle cell traits. 
 
A  S 
A  AA  AS 
   S  AS  SS 
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Figure 2-6: One parent has the sickle cell trait and the other is normal (Bloom, 1995). 
2.4 Complications 
Vaso-occlusive crises, or pain episodes, are severe and complicated forms of 
sickle cell disease that occur in all parts of the body.  According to Marlowe and Chicella 
(2002), vaso-oclusive episodes have been repeatedly reported as the most common cause 
for hospitalization of SCD patients, representing $475 million in annual health care 
expenditures and $75,000 in hospitalization costs. Adolescents and adults who suffer 
from vaso-occlusive crises experience severe and recurrent pain episodes throughout their 
lifetimes. The two types of vaso-occlusive pain are acute and chronic episodes. Acute 
vaso-occlusive episodes involve pain for periods of less than three to six months (Payne, 
1989).  
Marlowe and Chicella (2002) noted that acute sickle cell pain has been described 
by patients as being more severe than post-operative pain and as intense as cancer pain. 
Pain episodes can begin as early as 6 to 9 months of age and continue throughout 
adulthood, with episodes lasting for days or even weeks (Steinberg, 1999).  Recent 
studies suggest that children born with the SS genotype have a significantly median age 
A  S 
A  AA  AS 
A  AA  AS 
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of 1.9 years to first dactylitis episodes, compared to 3.9 years with those who are born 
with the SC genotype (Dampier, 2008). Also in terms of episodes, 40% to 50% of those 
children experience one pain episode per month, while 10% of other school-age children 
experience pain episodes more than twice a month (Dampier, 2008). 
Unfortunately, the underlying mechanism responsible for the onset of pain 
episodes remains ambiguous to researchers and experts who study SCD. Researchers 
believe that the onset of pain episodes can be provoked by changes in altitude, 
temperature, physical and emotional stress, menstruation, fatigue, and dehydration 
(Marlowe & Chicella, 2002). Steinberg (1999) indicated that, in a given year, up to 60% 
of patients with SCD experience severe pain episodes, with a small majority of patients 
suffering from severe pain almost constantly. 
Some patients with SCD require frequent hospitalization, while others seldom 
experience episodic pain (Gil, Abrams, Phillips & Keefe, 1989).  In addition, people with 
a range of mild to severe symptoms of SCD often complain of pain in four major parts of 
the body: the abdomen, low back, joints, and chest (Gil et al., 1989). Dampier’s (2008) 
research illustrated that the impact of pain episodes goes beyond the substantial use of 
health care resources. The impact of pain episodes has shown to have adverse effects on 
children’s physical functioning, school attendance, academic performances, and social 
roles.  
The management and prevention of pain episodes continue to be a major 
challenge for health care professionals and researchers. Although no known cure exists 
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for sickle cell disease, we can have room for improvement in the care process for sickle 
cell disease patients in the United States. Prabhakar (2009) noted a lack of thorough 
understanding of the pathophysiology of sickle cell disease, as well as observing that the 
primary focus of SCD clinical care revolves around treating the complications of SCD 
rather than focusing on the prevention of complications. Pain from vaso-occlusive crises 
is the most common clinical problem experienced by patients with SCD, and often 
necessitates emergency visits to hospitals.   
Much of the literature has confirmed that the most effective method of managing 
pain is to treat the underlying medical condition, which includes minimizing major 
factors associated with acute intravascular sickling (Payne, 1989).  Drug therapy 
continues to be the primary form of treatment for acute and chronic SCD pain. Major 
medical controversies regarding drug treatment include the use of narcotic analgesics for 
the management of SCD pain and the incidence of substance abuse among SCD patients 
treated with narcotic analgesics for pain (Payne, 1989).    
2.4.1 Stroke 
A childhood stroke is one of the many devastating complications caused by sickle 
cell disease that can result in permanent brain damage or death. A stroke is triggered by a 
decrease in the flow of oxygen due to a major disruption of the amount of oxygen to the 
brain. This complication can occur without warning.  Studies have found that the median 
age for a stroke in SCD is 6 years of age. Studies have also revealed that by the age of 14, 
a stroke has affected at least 8% of the SCD patient population, and by the age of 20, a 
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stroke has affected 11% of the patient population (Njamnshi, Mbong, Wonkam, Ongolo-
Zogo, Djientcheu, Sunjohy, 2006; Serjeant, 1997).  The reoccurrence rate for strokes for 
children within three years of SCD diagnosis is 50% to 70% (Serjeant, 1997).   
Transcranial Doppler Ultrasonography (TCD) and Magnetic Resonance Imaging 
(MRI) can be used to diagnose strokes. The TCD predicts the levels of risk for strokes by 
measuring mean blood velocity (Mazumdar, Heeney, Sox, & Lieu, 2007). The existing 
literature indicates a need for a more accurate diagnostic method for strokes other than 
the use of TCD. In addition, several research studies have shown a lack of educational 
materials about the effects of strokes, and these studies indicate a need for more stroke 
screening tests.  The extent of this problem was revealed in a cross-sectional study 
conducted by The Children’s Hospital of Philadelphia (CHOP) using a population of 44 
children with sickle cell disease and 50 caregivers (Katz, Whitley-Smith, & Frempong-
Ohene, 2002).  The research showed that 46% of the caregivers surveyed were unable to 
identify the warning signs of a stroke. In this study, only 34% of the caregivers could 
identify a stroke as being a complication associated with SCD (Katz et al., 2002). 
  2.4.2 Acute Chest Syndrome 
Acute Chest Syndrome (ACS) is a serious complication of sickle cell disease that 
contributes to the high rates of morbidity and mortality in SCD.  The ACS results from 
infections in the lung cavity caused by bacteria organisms. The ACS is a serious 
complication similar to pneumonia, and has been reported to occur in about 50% of sickle 
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cell disease patients; ACS has reoccurred in approximately 80% of SCD individuals 
(Fawibe, 2008).  
 The Acute Chest Syndrome ACS accounts for approximately 25% of premature 
deaths among SCD patients. No available laboratory, radiographic, or clinical methods 
accurately establish the etiology of ACS. Researchers argue that infection and fat emboli 
are the most readily identifiable causes of ACS (Bernard, Yasin, & Venkat, 2007; Fawibe 
2008). The most common diagnostic symptoms in all age groups are fever, coughs, 
abnormal chest x-rays, and chest pains. Less common symptoms include shortness of 
breath, productive cough, and wheezing (Bernard et al., 2007).   
2.5 Treatments 
Hydroxyurea is a popular cytostatic myelosuppressive, chemotherapeutic agent 
drug approved by the FDA in 1998 for adult sickle cell disease patients (Weiner & 
Brugnara, 2003).  For many decades, hydroxyurea was used as a chemotherapeutic drug 
to treat cancer. Hydroxyurea is currently used to decrease sickle cell hemoglobin 
polymerization and erythrocyte sickling by increasing fetal hemoglobin (HbF) 
production, a hemoglobin found in newborn babies (Weiner & Brugnara, 2003). This 
drug has successfully reduced the number of painful periods and the recurrence of 
prevalent SCD complications. Physicians recommend that individuals who experience 
frequent painful episodes or who have a history of acute chest syndrome, symptomatic 
anemia, and other vaso-occlusive episodes are candidates for hydroxyurea therapy 
(Mehta, Annan-Afenyi, Byrns, & Lottenberg, 2006).  
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Adults in a random placebo-controlled trial study with hemoglobin SS, who were 
receiving hydroxyurea, exhibited a significant reduction in vaso-occlusive crises and the 
incidence of acute chest syndrome as a result of hydroxyurea therapy (Mehta et al., 
2006). In this study, painful episodes decreased from 4.5 to 2.5 painful crises per year 
(Mehta et al., 2006). A similar double-blind study, which involved placebo-controlled 
trials of hydroxyurea with 299 adult SCD participants, terminated after 28 months of 
treatment because hydroxyurea reduced the frequency of pain episodes in patients along 
with the frequency of episodes of acute chest syndrome (Steinberg, 1999).  
  The U.S. Food and Drug Administration (FDA) has not approved hydroxyurea 
treatment for use by infants and children.  Studies of hydroxyurea in young children are 
in the early stages, and long-term follow-ups need to ascertain the risk of continuing 
adverse side effects on children (Mehta et al., 2006).  A pilot study of hydroxyurea by the 
National Heart, Lung, and Blood Institute (NHLBI) evaluted whether or not hydroxyurea 
can benefit young patients. Participants who ranged from 6 to 24 months of age 
demonstrated that the drug is well tolerated in younger children.  Scientists predict that 
this drug will be an important factor in emergent countries. Many developing countries 
do not have the facilities necessary to safely perform bone marrow transplants and 
transfusions.  
Hydroxyurea has been described as a cost- effective treatment. Moore, Charache, 
Terrin, Barton, & Ballas (2000) examined the cost-effectiveness of hydroxyurea therapy 
and found a total cost savings of almost $26 million a year if every eligible patient in the 
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United States were taking hydroxyurea (Lanzkron, Haywood, Hassell, & Rand, 2008; 
Moore et al., 2000). Moore et al. (2000) study results showed (see Table 2) that 
hydroxyurea averaged $16, 810 for the annual medical care cost for patients while those 
cost of control patients averaged $ 22,020 (Nietert, Silverstein, & Abboud, 2002).  
2.5.1 Over-the-counter Drugs 
Over-the-counter medicines, such as nonsteroidal anti-inflammatory drugs 
NSAIDs, acetaminophen (Tylenol), ibuprofen (Advil or Motrin), as well as opioids, such 
as codeine, morphine, and oxycodone, are used to control sickle cell pain.  Non-opioids 
are prostaglandin-synthesis inhibitors, prescribed for the management of mild pain and 
used in conjunction with opioids (Stinson & Naser, 2003). Non-opioids prevent the 
conversion of arachidoinc acid to prostaglandins by interfering with the function of the 
enzyme cyclo-oxygenase (COX) (Stinson & Naser, 2003). Non-opiods can provide 
additive analgesia when combined with opioids.  Acetaminophen is another popular drug 
use for the treatment of sickle cell disease. Acetaminophen is described as one of the 
safest analgesics, and it inhibits the synthesis of prostaglandins. On the other hand, 
NSAIDs are prescribed for patients with gastritis, peptic ulcer, and renal failures. Opioids 
are a popular analgesic used for the treatment of moderate and severe acute pain due to 
pain episodes (Stinson & Naser, 2003).  
2.5.2 Transfusion Therapy 
Transfusions are another method of trying to deal with SCD complications and 
assisting with the prevention of strokes and acute chest syndrome. Transfusions are 
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recommended for use of SCD patients with acute chest syndrome, heart failure, and 
severe anemia (in children) who have enlarged spleens, multi-organ failure syndrome, 
splenic sequestration, aplastic crisis, and who are susceptible to strokes (Claster & 
Vichinsky, 2003). Transfusion therapy seeks to increase the concentration of hemoglobin 
A and reduce the percentage of sickle hemoglobin to increase the oxygen carrying 
capacity of blood (Claster & Vichinsky, 2003).   
A clinical trial study, which evaluated the efficacy of transfusions among patients 
with some SCD complications, showed that repeated transfusions reduce the risk of 
recurrent strokes in children with SCD.  This study also showed that researchers were 
able to predict that 50% of children with SCD, who had suffered strokes and had not 
received transfusions, would suffer strokes within three years compared to 10% of SCD 
individuals who had receivied transfusions (Steinberg, 1999).  
2.5.3 Bone Marrow Transplantation 
Bone marrow transplantation is an experimental therapy limited to candidates 
below 16 years of age and who exhibit SCD complications, such as a stroke, acute chest 
syndrome, and refractory pain (Steinberg, 1999). Statistics show that only 1% of patients 
with sickle cell anemia actually meet the set requirments for bone marrow transplantation 
(Steinberg, 1999). In 1984, a bone marrow transplant was used to treat a pediatric patient 
with leukemia. The transplant also cured the patient’s sickle cell disease (NIH, 2002). 
 Researchers have found that the mortality rate from this procedure is 10% and 
that it requires SCD patients to undergo a chemotherapeutic regimen prior to transplant.  
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Consequently, some SCD patients do not survive the chemotherapy process whereas 
others may sufffer from life-threatening infections before their bone marrow and immune 
systems are sufficiently regenerated (NIH, 2002). Potential complications include graft 
rejection and graft versus host disease (GVHD).  Currently, transplants are still 
considered only for sickle cell disease patients whose disease is severe enough to justify 
the risk. The National Heart, Lung, and Blood Institute (2002) is looking for various 
methods to reduce the risk of bone marrow transplantation. The blood from a baby’s 
umbilical cord is believed to reduce the risks of rejection and graft-versus-host disease. 
Also, this blood does not need to match the recipient’s blood as closely as bone marrow 
donors (NHLBI, 2002).  
2.6 Experimental Treatment  
Gene therapy is a new treatment for patients with sickle cell anemia. Researchers 
believe that gene therapy is an improvement over blood transfusion because it offers a 
more permanent solution. Gene treatment requires a delivery system that can carry a 
normal gene to cells that contain defective genes (Jones, 2008).  Scientists have chosen 
modified viruses as an efficient delivery system. Normal genes are delivered to the target 
cells to ensure that the normal genes function as they should (Jones, 2008). Gene therapy 
research is still in an early stage, and many scientists believe that this method could be 
the clinical cure for sickle cell anemia.  
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2.7 Government Initiatives   
The 1972 Sickle Cell Disease Control Act was the first law to mandate funding 
for scientific research programs on sickle cell disease.  Such programs were designed to 
improve the quality of life and care for patients with sickle cell disease. These programs 
aimed at reducing the percentage of deaths from sickle cell anemia by promoting research 
on treatment and prevention (Bonds, 2005; Jones, 2008).  
2.7.1 Sickle Cell Treatment Act 
  President George W. Bush signed the bipartisan Sickle Cell Treatment Act into 
law in 2003.  This law granted states to get federal funding for patient counseling, 
educational initiatives, and community outreach programs (Haywood, Hassell, & Rand, 
2008; SCDAA, 2005). According to the Sickle Cell Disease Association of America, 
patients can receive federal matching funds for sickle cell disease-related services under 
Medicaid. 
2.7.2 United States Postal Service  
  In 2004, the U.S. Postal Service issued a stamp to promote sickle cell disease 
awareness. The image, created by artist James Gurney, depicts a mother holding her 
baby. The stamps have an inscription: “Test early for sickle cell” (Jones, 2008).  The 
stamp was created to emphasize the importance of early SCD testing, and it provided the 
U.S Postal Service with a means of raising public awarness on sickle cell disease (Jones, 
2008).  
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2.8 Newborn Screenings 
Newborn screenings are believed to be the most effective and efficient screening 
programs for the detection and diagnosis of inherited diseases (Bioethics, 2001). 
Newborn screening programs were designed to help physicians identify newborns with 
SCD and to allocate penicillin prophylaxis to help reduce the incidence of pneumococcal 
sepsis in infants. Before government laws mandated the screening of newborns for SCD, 
the rate of mortality approached 30% by age 3, and most deaths were due to sepsis and 
acute anemic events (Reed &Vichinsky, 1998).    
Early screening for the sickle cell trait and treatment for sickle cell disease can 
substantially reduce the risk of serious infection during the early years of life (U.S. 
Preventive Services Task Force, 2007). Follow-up sickle cell screening and counseling 
have shown to be the most effective methods of helping families with infants who have 
been identified as having the sickle cell trait. Although all states now screen for sickle 
cell disease, this disease remains less familiar to the public compared to other blood 
disorders found by early screenings, such as phenylketonuria (PKU) and hypothyroidism  
(Yang, Andrews, Peterson, Arvind, & Cepeda, 2000).  
2.9 Genetic Counseling 
Parents who receive genetic counseling and support learn how to assess 
respiratory distress, fever, jaundice, and splenomegaly, which are early major 
complications of SCD. (Claster & Vichinsky, 2003).  Research has confirmed that the 
follow-up genetic counseling rates for infants with sickle cell disease and other 
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hemoglobinopathies ranges from 35% to 60% nationwide.  These low rates indicate that 
many families are not complying with follow-up procedures for infants with sickle cell 
disease.  
Cultural views, social and economic barriers, guilt, and health beliefs may 
contribute to the lack of interest and support for sickle cell testing and genetic counseling 
(Gustafson, Gettig, Morse, Krishnamurti, & Lakshmanan 2007; Yang, Andrews, 
Peterson, Arvind, & Cepeda, 2000).  Articles on prenatal sickle cell screening education 
suggest that many factors contribute to the lack of follow-up counseling and screening. 
These factors include anticipatory anxiety on the parents’ part about learning that their 
infant has a sickle cell hemoglobinopathy, denying and avoiding the possibility that their 
child might be born with sickle cell disease, and fear of being responsible for causing the 
disease  (Yang et al., 2000). In addition, Hill (2001), the author of Care Giving in 
African-American Families: Caring for Children with Sickle Cell Diseases, discussed 
that fathers are usually less likely to know they are carriers of the sickle cell trait and are 
more than likely to deny their contribution to passing on the disease. 
The lack of awareness of newborn screening programs is another key factor that 
contributes to low follow-up rates. The follow-up rate for newborn screenings may 
increase significantly only if the parents of infants with sickle cell hemoglobinopathies 
become informed and aware of the significance of the screening program during prenatal 
education sessions (Yang, Andrews, Peterson, Arvind, & Cepeda, 2000). Hill (2001) 
stated that many mothers experience feelings of helplessness and fear because of the SCD 
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diagnosis. Hill (2001) concluded that mothers receive little information from physicians 
regarding how to care for their SCD children. This information further demonstrates a 
lack in awareness of SCD as a result of poor patient-physician relationships.  
2.10 Patient and Physician Relationship 
It is particularly important for sickle cell disease patients to develop trust in their 
medical professionals, especially those who underutilize recommended medical therapies 
(Haywood, Lanzkron, Ratanawongsa, Bediako, Lattimer, & Powe, 2010).  Sickle cell 
disease patients develop a sense of mistrust for clinicians for various reasons: not being 
considered as partners in the medical relationship, negligence while being hospitalized, 
and doubting the legitimacy of SCD pain (Haywood et al., 2010). Haywood et al. (2010) 
noted that adults with sickle cell disease are likely to be more aware of their illness than 
some health care workers, yet many patients have reported in qualitative studies that their 
acute health care providers do not have their best interest at heart and fail to prescribe 
treatment applicable to their medical needs.  
In addition, studies that have observed the physician communication behaviors 
between African-Americans conclude that physicians are shown to exhibit less empathy, 
courtesy, and attention to African-American patients (Haywood et al., 2010). In one 
study, Haywood et al. (2010) also noted that physicians rated African-American patients 
more negatively when scoring on intelligence, education level, and the likelihood of not 
to complying with medical advice, as well as abusing medication. Haywood et al.’s 
(2010) study on the results of the association of medical provider communication and 
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trust among sickle cell disease patients’ showed an association between the health care 
provider relationship and sickle cell disease patient’s trust. Ninety-five adults with sickle 
cell disease were tested in this study.  This study illustrated a 3.76% increase in trust 
scores from sickle cell disease patients when there was a 10% increase in provider 
communication ratings (Haywood et al., 2010). Researchers therefore concluded that 1) a 
poorer patient rating of provider communication will result in a decrease in trust among 
patients, and 2) communication has a direct effect on a patient’s receptiveness to his/her 
physician (Haywood et al., 2010). 
2.11 Health Care Professionals’ Perceptions and Knowledge of SCD 
For patients to receive quality and efficient care, it is imperative that health care 
professionals and caregivers are aware of how to treat SCD.  A study at Southern 
University Teaching Hospital in Baton Rouge, Louisiana, showed that health care 
workers, especially nurses, have major difficulty treating patients with chronic illnesses, 
such as sickle cell disease, because SCD patients do not fit into the preconceived “sick 
role” found among hospital patients with acute illnesses (Mabien, Labbe, Herbert, & 
Haynes, 2001). Nurses have been reported to assess SCD patients’ sickle cell pain less 
seriously than for patients who do not have SCD (Mabien et al., 2001).  
The preconceptions of health care professionals regarding SCD results from a 
lack of understanding of how to treat patients coupled with the fear of creating pain killer 
addicts when distributing medicine to SCD patients (Mabien et al., 2001). Health care 
professionals continue to mistreat SCD patients, particularly minorities, by withholding 
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the requisite analgesics. Chestnut (1994) challenged the issue of race and gender in his 
Service Perception Test (SPT), a pilot study that examined how ethno-cultural factors of 
age, race, and gender were perceived as influencing the quality of health care received by 
patients.   
Chestnut’s (1994) study results showed, without fail, that 1) white patients were 
perceived to get better sickle cell care than blacks, 2) young children were provided with 
better care than the elderly, and 3) the elderly were provided with better care than middle-
aged adults (Prabhakar, 2009). Moreover, when SCD patients remain untreated, studies 
show that they are predisposed to developing pseudo-addictive behavior (Marlow & 
Chicella, 2002), which causes patients to seek and hoard drugs due to the fear of future 
pain. Pseudo-addictive behavior ends when patient pain is properly managed and patients 
receive the proper dosage of medication. Sickle cell disease and pain management 
literature dispelled several myths about SCD.  Studies have shown that SCD patients are 
no more susceptible to developing an addiction to pain medication than any other group 
of patients  (Jacob, 2006). A patient care study conducted at Southern University 
Teaching Hospital, using a sample composed of licensed practical nurses, pediatric 
nurses, and registered nurses, showed a lack of empathy for SCD patients on their part. 
This study revealed a lack of understanding of SCD and pain for SCD patients (Mabien. 
Labbe,  Herbert, & Haynes, 2001).  Health care providers managed to show some level of 
sympathy for patients with cancer pain, post-operative pain, and pain due to trauma. On 
the other hand, providers still found it challenging to sympathize with people who 
experienced SCD pain (Mabien et al., 2001).  
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2.12 Sickle Cell Knowledge 
During the past four decades, the federal government has made significant strides 
in providing funding and research on SCD.  However, much of the reviewed literature 
shows a lack of knowledge on SCD among at-risk populations. In a study by Boyd et al. 
(2005), 264 African-American women between the ages of 18 and 30 from St. Louis, 
Missouri, participated in a cross-sectional telephone survey on SCD. These authors found 
that 30% of the African-Americans contacted had no prior knowledge of SCD and were 
released from their study.  Of the 162 women who met the eligibility criteria, only 9.3% 
understood the inheritance pattern of SCD, and 11% were unaware of their carrier status 
(Boyd et al., 2005).  
In addition, participants did not understand treatment strategies for SCD, yet most 
participants were well aware that SCD is a defective blood disorder and that pain 
episodes are a major complication (Boyd et al., 2005). This study provided strong 
evidence that African-American women in their prime reproductive age are still not 
equipped with adequate information on SCD, SCD incidence, and inheritance patterns 
(Boyd et al., 2005). Such general information is essential when making informed 
decisions on having a child (Boyd et al., 2005). 
Treadwell et al. (2006) surveyed 282 people from northern California about their 
exposure to and knowledge of sickle cell disease and sickle cell traits. Interestingly, 68% 
of those interviewed in this study responded correctly to knowledge questions about 
SCD. Only 15% of the respondents were aware of their own trait status.  A majority of 
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respondents reported that they received SCD testing at their local community, hospital, 
and clinic (Treadwell et al., 2006).  
Ogamdi (1994) evaluated the general knowledge of SCD among 334 students 
from a university in southeastern Texas. Study results illustrated that approximately 81% 
of students were not unaware of the genotype describing SCD, and more than 60% of 
students were unaware that SCD is a preventable disease if individuals made 
“responsible” reproductive decisions (Ogamdi, 1994). On the other hand, 63% of students 
were able to correctly answer knowledge questions regarding symptoms of SCD. A 
significant limitation of this study was that not all questionnaire responses were reported 
in frequencies. However, this researcher has concluded that individuals between the ages 
of 19 and 30 lack the understanding of basic facts concerning SCD. A need exists for 
more sickle cell screenings, education, and counseling among university students. 
In a similar study, Stewart and colleagues conducted a mixed-method study using 
a sample of 191 African-American college students from the Southeast who ranged from 
19 to 30 years of age (Prabhakar, 2009).  Their study focused on examining the 
knowledge and belief systems surrounding SCD, the SCD trait, and genetic testing 
among young African-American adults (Prabhakar, 2009). The investigators found a lack 
of knowledge regarding carrier status, family history, and genetic testing among the 
target group (Prabhakar, 2009).  
Finally, in a research study designed by Dyson (1997), 104 carriers and non-
carriers of SCD were evaluated on their knowledge and awareness of SCD. Results 
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showed that participants poorly understood questions related to patterns of inheritance. 
Participants answered only 25% and 29% of the inheritance questions correctly. 
Interestingly, no significant difference occurred in knowledge of SCD among carriers and 
non-carriers. Both scores were believed to be “strikingly” similar by the researcher 
(Dyson, 1997). Three carrier participants claimed to receive counseling, but no 
significant differences occurred between those counseled and those not counseled. This 
study had several limitations. With 104 participants, only 55 completed the survey. 
Researchers believed this discrepancy to be a result of incomplete or inaccurate 
addresses, as well as several methodological oversights.  
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2.13 Conclusion 
Sickle cell disease is a disease that affects more than 100,000 African-Americans 
in America. After reviewing much of the literature on this subject, this researcher    
determined that a great need exists for more research and education on this disease, 
especially for more research studies that examine SCD awareness among various ethnic 
populations in America. The scarcity of SCD research illustrates how our society fails to 
view sickle cell disease as a serious illness. Currently, our society’s attention is on non-
inherited blood disorders, for example, HIV/AIDS, hypertension, and cancer. Without 
awareness and a public outcry for a cure and more funding, sickle cell disease will 
continue to be a silent killer to  young men and women around the world.  
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CHAPTER 3 
RESEARCH METHODS 
3.1 Participants 
Participants in this study were undergraduate students from the University of 
Illinois, at Urbana-Champaign who were enrolled in one of the three following 
Community Health courses: Community Health Organizations (CHLH 210), Health Care 
Systems (CHLH 250), and Introduction to Medical Ethics (CHLH 260).  The exclusion 
criteria for this study included any person not enrolled in the Community Health courses 
210, 250, and 260, unwillingness to participate, and students under the age of 18.  Two 
hundred fifty-nine (259) questionnaires were distributed among the three classes.  The 
use of undergraduate participants as the study sample followed the procedures and 
guidelines set forth by the University of Illinois at Urbana-Champaign and the 
Institutional Review Board (IRB) (see Appendix C).  Participants were not placed in 
physical, emotional, or academic harm at any time during the course of the study.  The 
study design was reviewed and approved by the IRB. 
3.2 Procedures/Materials 
The Sickle Cell Disease (SCD) questionnaire was administered to all eligible 
participants between November and December 2008. Before the questionnaires were 
distributed, a consent form was read and distributed to all students for their review (see 
Appendix D).  The consent form informed participants that the research study was 
voluntary and that they would not be placed at any risk following the completion of the 
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study.  After the consent form was read and distributed, students had approximately 10 to 
15 minutes to complete their questionnaire in class under the supervision of their 
professor.  To maintain the confidentiality of all participants, names and signatures were 
not retrieved on the questionnaires.  Members of the research team collected the 
questionnaires to protect the anonymity of participants. All consent materials and 
questionnaires were stored in a secure office. 
 3.3 Survey Instrumentation  
 The instrument used for this study was a structured questionnaire containing 
multiple choice questions and fill-in-the-blank demographic questions.  Section 2 
contained 11 multiple-choice questions that tested students’ knowledge of clinical 
characteristics of sickle cell disease, populations at risk for developing SCD, screening 
and counseling methods, incidence, and prevalence rates.  Two faculty members of the 
Community Health Department reviewed the questionnaire.  Descriptive questionnaire 
data were processed and analyzed in the Statistical Service Database for Windows 
(SPSS).  
3.4 Study Measure 
All questionnaire data were entered into the SPSS database and coded by using a 
numerical system.  The questionnaire contained four categories of race identification for 
participants to identify: 1) Caucasian, 2) African-American, 3) Hispanic, and 4) Other.  
Gender was coded as 1) male and 2) female. Age was determined by students filling in 
the blank. Ten sickle cell disease questions were listed on the questionnaires. Frequency 
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tables, cross-tabulations, and chi-square tests were used to evaluate the variations of 
existing SCD knowledge among students and the statistically significant alpha p value (p 
= 0.05) was used to determine variations in response rates.  Frequency tables were 
divided by ethnicity and response results, whereas cross-tabulation tables grouped all 
response variables together by ethnicity per result question. The chi-square test was used 
to group students’ response rates by gender and ethnicity.  
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CHAPTER 4 
RESULTS 
4.1 Response Rates 
Two-hundred fifty-nine questionnaires were distributed to students at the 
University of Illinois at Urbana-Champaign in three community health courses. Although 
259 participants were included in the analysis, not all participants responded to each 
question.  Percentages reported in this study are analyzed results from the total number of 
participants who responded to each question.  Those questions left unanswered were 
coded as (0) and did not conflict with the overall analysis and study.  
4.2 Sample Description   
 
Each participant’s demographic information is shown in Table 5.  Of the 259 
participants who responded to the questionnaire, approximately 54% of the respondents 
identified themselves as Caucasian, 22% identified themselves as being African-
American, 0.6% identified themselves as Hispanic, and 17% identified themselves as 
“Other.”  The majority of students who identified themselves as “Other” were of Asian 
and Pacific-Islander descent.  
4.2.1 Gender 
The average age for participants was 20 years old (see Table 3), and the age range 
varied between 18 and 29 years of age.  Approximately 69.1% of the participants 
identified themselves as female, 30.1% of the participants identified themselves as male, 
and 1% of the participants remained unresponsive. 
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4.3 Knowledge of Sickle Cell Disease 
The knowledge questions that focused on sickle cell disease were evaluated by 
calculating the number of correct and incorrect responses for each participant in SPSS for 
Windows.  Approximately 92.7% of the participants were able to identify sickle cell 
disease as being an inherited blood disorder. Eighty-one percent of the participants knew 
that sickle cell disease evolved from Africa.  On the other hand, only 17% of the 
participants were able to identify the number of new births born with sickle cell disease.  
Interestingly, 84.9% of the participants were able to identify the clinical manifestation of 
sickle cell disease.  
Out of the total number of participants, 94.2% correctly identified that no cure for 
sickle cell disease exists along with 91.1% of the students correctly identifying 
populations most at risk of developing sickle cell disease.  Only 78.8% of the students 
could identify that sickle cell anemia is a medical condition in which the red blood cells 
develop an unusual shape, and 89.2% identified the appropriate time to test for sickle cell 
disease.  Table 8 shows that only 43.6% of the participants were able to identify the 
appropriate steps to take for women of childbearing age diagnosed with sickle cell 
disease.  
4.3.1 Age 
Approximately 62.7% of the participants were ages 18 to 20, 62% were ages 21 to 
25, and 36% were ages 26 to 29 Generally, all age groups showed prior knowledge of 
sickle cell disease.  The number of correct responses decreased when students were asked 
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specific questions regarding the incidence and prevalence rate of sickle cell disease, as 
shown in Table 11.  Only 15.4% of the students ages 18 to 20, 6.2% of the students ages 
21 to 25, and 33.3% of students ages 26 to 29 correctly answered Question 3, which 
asked: “In the United States, how many babies are born with sickle cell disease per year?”  Only 
37.6% of the students ages 18 to 20, 43% of the students ages 21 to 25, and 66.6% of the 
students ages 26 to 29 correctly responded to Question 9, which asked: “What is the 
estimated number of people living with sickle cell disease in the United States?”  No 
statistical differences in the variation of response rates occurred between the three age 
groups. 
4.3.2 Gender 
A total of 30.2% males and 69.3% females completed the sickle cell disease 
questionnaire.  Both genders had a general understanding of sickle cell disease from a 
medical standpoint.  However, results showed that 20.5% of males and 15.7% of females 
were able to identify how many babies were born in the United States per year with sickle 
cell disease. The results showed that 38.5% of males and 40.7% of females responded 
correctly to the number of people living in the United States with sickle cell disease.  
In addition, only 48.7% of male students and 42.5% of female students were able 
to correctly identify the estimated life expectancy of people living with sickle cell 
disease. Question 4 was significant for the Pearson’s chi–square result (p = .047).  A 
significant difference occurred in knowledge between males and females when compared 
to previously discussed questions.  As shown in Table 10. male and female students were 
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more likely to respond correctly to the following questions: Question 10: “Is there a cure 
for sickle cell disease”; Question 11: “What population is more at risk for developing 
sickle cell disease”; Question 12: “Sickle cell anemia is a medical condition where the 
red blood cells____?; and Question 13: “When is the appropriate time to test for sickle 
cell disease?”  No statistical differences in the variation of response rates occurred 
between male and females for questions 11 to 14. 
4.3.3 Ethnicity 
Table 9 also illustrates that 85.1% of Caucasian students, 78.9% of African- 
American students, 75% of Hispanic students, and 71.1% of “Other” students were 
knowledgeable about the origins of sickle cell disease.  Interestingly, 18.4% of Caucasian 
students, 7% African-American students, 18.7% of Hispanic students, and 24.4% of 
“Other” students correctly responded to Question 3: “In the United States, how many 
babies are born with sickle cell disease per year?” Only 41.8% of Caucasian students, 
47.4% of African-Americans students, 37.5% of Hispanic students and 48.8% of “Other” 
students were aware of the average life expectancy of people living with sickle cell 
disease (Question 4).  
The percentages of Caucasian students who correctly identified the medical 
complications caused by sickle cell disease were 85.8%, 84.2 % for African-Americans, 
87.5% for Hispanic students, and 84% for “Other” students. Additionally, 38.6% of 
Caucasian students, 47.4% of African-American students, 37.2% of Hispanic students, 
and 38.6% of “Other” students responded correctly to the number of people living in the 
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United States with sickle cell disease (Question 9). Approximately 95% of Caucasian 
students, 96.5% of African-American students, 100% of Hispanics, and 88.8% of “Other” 
students identified that no cure for sickle cell disease exists (Question 10).  In addition, 
42.1% of Caucasians students, 40.1% of African-American students, 56.2% of Hispanic 
students, and 48.8% of “Other” students could correctly identify the appropriate actions 
for women of childbearing age, who are diagnosed with sickle cell disease, to take when 
trying to conceive. This study showed that no statistical difference existed in the variation 
of response rates between ethnicities. 
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CHAPTER 5 
DISCUSSION 
5.1 Study Findings 
The research study was designed to examine whether or not college students 
attending the University of Illinois at Urbana-Champaign (UIUC) had any prior 
knowledge of sickle cell disease. Three research questions were used as the primary 
framework for this study. Research Question 1 asked, “How knowledgeable are 
midwestern college students on background information regarding sickle cell disease?” 
Study results revealed that participants had some existing knowledge of this disease. 
However, among the sample group of college students, all of them scored the lowest 
when questioned on the prevalence and incidence rates of this disease (see Table 6).  
Only 17% of the students answered Question 3 correctly, which asked, “In the United 
States, how many babies are born with sickle cell disease per year?” Thirty-nine percent 
of the students responded correctly to Question 9, which asked, “What is the estimated 
number of people living with sickle cell disease in the United States?”  
Moreover, findings from this study are similar to other published sickle cell 
disease studies concerning participants being more aware of the patterns of inheritance of 
SCD, as well as the prevalence and incidence rates of SCD. A research study conducted 
by Boyd et al. (2005) showed that students scored low on questions that focused on the 
inheritance patterns of SCD.  Boyd et al. (2005) showed that 9% (15/162) of the 
participants understood the inheritance pattern of SCD.  In addition, in a study by Dyson 
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(1997), only 25% of the participants correctly answered questions on the inheritance 
patterns of SCD. These results indicate that individuals are unaware that they could be 
carriers of this disease and could be at risk of producing an offspring with SCD or the 
sickle cell trait. The basic knowledge of knowing how many people are born and living 
with this disease is crucial. Again, Table 6 (see Appendix B) shows that college students 
are not familiar with how many people are living with this disease. The results from this 
study showed that only 17% of UIUC students correctly identified how many babies are 
born with sickle cell disease per year, and 39.8% correctly responded to the number of 
people living with sickle cell disease in the United States. It is imperative for people to be 
aware of their SCD or SCT status, as well as knowing general information about this 
disease. 
 Research Question 2 in the study asked, “Do any significant differences exist in 
awareness between ethnic groups or groups of students who have a higher probability of 
inheriting sickle cell disease traits?” Results showed no significant differences between 
ethnic groups, especially among African-American students who are most at risk of 
inheriting the sickle disease trait.  In this study, African-American students failed to 
know more about sickle cell disease than their Caucasian, Hispanic, and “Other” 
classmates. Therefore, this research study illustrates that college students have some 
existing knowledge about sickle cell disease. Yet the overall reviewed literature on sickle 
cell disease collectively stresses that a dire need remains for more extensive research and 
awareness programs to reach at-risk populations on the severity of this disease and the 
importance of knowing if an individual is a carrier of the sickle cell trait. It is imperative 
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that at-risk populations are well informed on the medical complications caused by sickle 
cells disease, as well as their carrier status. This information will help them make an 
informed decision on reproduction and genetic counseling options.  
Research Question 3 asked, “Do any significant differences exist in awareness 
between gender groups?” Results showed a significant difference in response rates for 
males and females who answered Question 4, which asked, “What is the estimated life 
expectancy of people living with sickle cell disease?”  The statistical difference for 
Question 4 was (p = .047), and therefore only 42.5% (see Appendix B) of the females 
answered the question correctly while 48.7% of the males responded correctly.  
By and large, the estimated life expectancy for people living with SCD is the mid-
40s and 50s while the average life expectancy for humans without SCD ranges from the 
early to mid-70s. People living with sickle cell disease are estimated to lose 30 years of 
life in comparison to others living without this disorder. The estimated difference is great, 
and it is crucial for the public to know the biological and physical effects of sickle cell 
disease. In addition, people who develop this disease suffer from medical complications 
and costly medical bills. They are constantly seeking medical treatments in order to live a 
normal and productive life. To have a shortened life span due to this disease can be 
tragic. Continued research on sickle cell disease must be done to help improve the lives 
of people stricken with this disorder. It is also important for our generation to know how 
short the life expectancy is for people living with sickle cell disease. as well as the severe 
health problems sickle cell individuals face throughout their lifetime. 
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5.2 Limitations 
As with any research study, this particular study had several limitations. This 
research study was designed only to sample students enrolled in three Community Health 
courses. Surveying students in Community Health courses limited the participant sample 
and excluded other university students who were less knowledgeable about this disease 
because they were not exposed to this medical disease in classes and/or at a risk of being 
a carrier of the sickle cell disease trait. Different results may have been obtained in a 
larger sample of students who were not all enrolled in Community Health classes.  
 This research study’s questionnaire also had several limitations. The 
questionnaire failed to include questions that would have specifically inquired how and 
when participants became knowledgeable about SCD. These questions are important and 
could be used to help determine the preferred method to educate college students about 
SCD.  Thus, such information could provide a framework for developing additional 
health education programs on sickle cell disease on campus and in the community. Not 
only was it important to question how students became knowledgeable about this disease, 
but also if they had the disease or knew anyone with the disease. That valid information 
would have helped determine if they were familiar with the disease due to being exposed 
to a person living with SCD.  
The questionnaire failed to capture the marital status and or sexual relationship of 
participants. This information would have allowed further analysis of at-risk populations’ 
awareness of SCD. This information would have also indicated a possible need for more 
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research on campus on SCD genetic and counseling for the university students. In 
addition, these results reflected responses only from college participants’ ages of 18 to 
30.  The awareness in this segment is important because the majority of births occur 
within this age range, and it is important for all young adults to be aware of this disease. 
If this study were extended to all participants in this age range, it would have more 
validity in the response rate. The questionnaire also did not record the participant’s 
economic background or status. Most people with a higher socioeconomic background 
are most likely to seek a physician’s care for health and medical issues due to their 
economic means. People from a lower socioeconomic background may not have the 
resources to follow up with a physician and seek proper care due to their lack of finances. 
Lastly, the questionnaire did not include a segment on SCD inheritance patterns. The 
inheritance patterns are important when producing offspring. Couples must be aware that 
the probability is higher for producing a child with sickle cell disease when both are 
carriers for the disease.  
5.3 Suggestions 
More research on the public’s general knowledge about this disease will help 
determine the areas where more education is needed on SCD.  The reviewed literature 
has focused on the biological genetics of this disease, but not much research has 
specifically addressed the awareness of this disease in all populations. Further studies are 
needed to address the effectiveness of intervening media campaigns to increase sickle cell 
awareness. It is important to evaluate which media source is most effective in increasing 
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the public’s awareness on this disease. We live in a technological age where Facebook, 
Twitter, MySpace, television/public radio commercials, web advertisement, and celebrity 
spokesmen are all currently a part of the marketing strategies used to inform the general 
public about a health disease or product. If this same approach was used to increase 
public awareness, more people would be informed about SCD, as well as their status as a 
carrier.  
Another factor that can help address this issue is placing a public figure in the 
forefront for sickle cell disease. Ideally, he or she could help start a movement on SCD 
awareness.  The public figure would more than likely generate additional funds for 
research, treatment, and even cures for SCD. Public interest would increase more medical 
training on this particular disease and help eliminate attitudes and preconceived notions 
of this disease. With more education and training, patients will be able to receive 
optimum care, and more centers can be built to specifically treat this disease in high-risk 
communities.  
  More research on health care professionals’ perceptions and practices on pain-
related SCD would also help increase sickle cell disease awareness in the medical world.  
The reviewed literature shows that some pain specialists who operate on sickle cell 
patients have inadequate knowledge on the disease’s related pain.  Therefore, physicians 
must continue to build strong relationships with patients who have SCD. Establishing 
centers that focus on this disease will allow more people to receive appropriate treatment 
and care. 
47 
 
 In addition, studies have not addressed sickle cell disease and interracial 
marriages. In the United States, we see a steady growth of immigrants from all over the 
world. Our world has become more diverse, and more couples are pushing the racial 
boundaries and marrying outside their race (see Figure 2-7). Researchers from the Pew 
Research Center for the People and the Press, an independent research organization, 
reported that one out of seven new marriages are multi-racial or multi-ethnic (Chen, 
2010).  
 
Figure 5-1: Interracial marriages 2005 (Microsoft News, 2007). 
An increase in interracial marriages among the millennial generation 18 to 29 year 
olds has occurred. Research shows that 85% of the millennial generation accepts 
interracial marriages, and more people from this age group are producing a new 
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generation of multi-racial children (Chen, 2010). Since interracial marriages are a 
growing trend, a need arises for more research on interracial marriages and how they 
correlate with sickle cell disease. Sickle cell disease will soon have an impact on all 
ethnicities and the gene will no longer be found primarily among African-Americans. 
Since this disorder will soon be a problem for all races, it is important that all ethnicities 
are knowledgeable about this disease and the effects that SCD has on the human body.   
In contrast to Chen (2010), Bloom (1995) argued that, due to natural selection, the 
Hb S gene has become less common among African-Americans in comparison to their 
African ancestors.  Bloom (1995) suggested that fewer African-Americans will have this 
particular trait. He believed that interracial mating and the decrease of needing a survival 
mechanism against malaria are causing the gene to be diluted over time. Bloom (1995) 
believed that these two factors explain why a reduction in the frequency of SCD in black 
Americans will occur. 
On the other hand, with an increase of sickle cell disease in our society, health 
care will became a main issue. An individual with this disease suffers from chronic health 
problems throughout his/her life. It is therefore imperative for treatment to be accessible 
to the public regardless of race, religion, gender, and sexual orientation. With a possible 
influx of urgent treatment for people with sickle cell disease, more SCD medical centers 
will need to be established. With sickle cell disease awareness in our communities and 
federal funding for addition SCD research, plus our government intervention to put a plan 
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into action to cover SCD medical expenses, will help the process of finding a cure to 
eliminate SCD around the world.   
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Table 1: Incidence of Sickle Cell Disease Genotypes 
                                                                                                            
                                                                                                         Type of Hemoglobin % 
 
Genotypes                    % of  SCD Children     Clinical Severity             S                A            F             C  
 
 
Hb SS                            71.9%              Usually Marked                        80-90                         2-10 
Hb S HPF                      0.1%                Asymptomatic                          60-80          0-2          15-35 
Hb SC                           20.0%              Mild to moderate                      45-55          0-2           0-8          45-50   
Hb S β°thalassemia      4.0%                Moderate to marked                 70-95           3-6          2-20 
Hb S β+thalassemia     4.0%                Mild to moderate                      50-90           2-30        0-20 
Hb SA                         Asymptomatic        38-48                                  48-62           0-2 
Source: Simon, Lobo, & Jackson. (1991). Current knowledge in the management of children and adolescents with  
 children and adolescents with sickle cell disease Part 1, physiological issues. Journal of Pediatric Nursing. 
Table 2: Cost-Effectiveness of Hydroxyurea  
Item                               Cost 
Mean Hospitalization Cost for Painful Crises 
without Hydroxyurea Regimen 
                           $ 17, 290 
 
Mean Hospitalization Cost for Painful Crises 
with Hydroxyurea Regimen 
 
                            $12,160 
 
Annual Average Hospital Cost  
per Patient on hydroxyurea 
 
                            $ 16, 810 
 
Annual Average Hospital Cost per patient not on 
Hydroxyurea 
 
                             $ 22, 020 
Source: Moore, Barton, & Ballas. (2000). Cost-effectiveness of hyroxyurea sickle 
cell anemia:Investigators of the multicenter study of hydroxyurea. American  
Journal of Hematology,26-31. 
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Table 3:  Respondents to Sickle Cell Questionnaire 
                                                                                                         
                          
  N 
N=259 
                    % 
Age of respondents    
 18-20 162  62.7 
 21-25 93 36.0 
 26-29 3 1 .2 
Gender    
 Male 78 30.2 
 Female 179                69.3 
Ethnic origin of 
respondents 
   
 African-American 57 22.0 
 Caucasian 140 54.0 
 Hispanic 16    6.0 
 Other 45 17.0 
Note. For “Other” students, students, were able to identify themselves by filling in the blank for ethnicity. 
 
 
 
Table  4: Percentage  of  Correct Responses for Biological Aspect of Sickle Cell Disease 
               Question #            Question  Percent (N) 
 
1 
 
What is sickle cell disease? 
 
  92.7 (259) 
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Table 5: Percentage of Correct Responses for Sickle Cell Disease Origin 
                 Question #             Question      Percent (N) 
2 Sickle cell disease evolved in 
which of the following 
continents? 
      80.7 (258) 
 
12 
 
Sickle cell anemia is a medical 
condition where the red blood 
cells….? 
 
      78.8  (258) 
 
Table  6: Percentage of Correct Responses for Incidence and Prevalence Rates of     
Sickle Cell Disease 
                 Question #             Question            Percent  (N) 
3 
 
In the United States, how many 
babies are born with sickle cell 
disease per year? 
             17  (258)  
4 What is the estimated life 
expectancy of people living with 
sickle cell disease? 
             44  (259 ) 
9 What is the estimated number of 
people living with sickle cell 
disease in the United States? 
            39.8 ( 257) 
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Table 7:  Percentage of Correct Responses for Medical Aspects of Sickle Cell 
Disease 
                  Question #            Question                 Percent (N) 
5 What medical complications are 
caused by sickle cell disease 
                   84.9 (257)  
10 Is there a cure for sickle cell 
disease? 
                   94.2 (258) 
11 What population is more at risk for 
developing sickle cell disease? 
                    91.1 (257) 
 
Table 8: Percentage of Correct Responses for Genetic Counseling and Screening 
                        Question #          Question            Percent (N) 
13  When is the appropriate time to test 
for sickle cell disease? 
               89.2  (258)  
 
14 
 
What is the appropriate action for a 
person of child-bearing age 
diagnosed with sickle cell disease? 
              43.6 ( 258)  
Note: All participants are of childbearing age. 
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Table 9: Percentage of Correct Responses by Participants Grouped by Ethnicities 
Ethnicities    N   Q1  Q2  Q3  Q4  Q5  Q9  Q10  Q11  Q12  Q13  Q14 
African-
American 
57.0 96.5 78.9 7.0 47.4 84.2 47.4 96.5 93.0 80.7 87.7 40.4 
 
Caucasian 
 
140 
 
93.6 
 
85.1 
 
18.4 
 
41.8 
 
85.8 
 
 8.6 
 
95.0 
 
92.8 
 
81.4 
 
90.7 
 
42.1 
 
Others 
 
45 
 
95.9 
 
71.1 
 
24.4 
 
48.8 
 
84.0 
 
38.6 
 
88.8 
 
86.6 
 
77.7 
 
93.3 
 
48.8 
 
Hispanic 
 
16 
 
94.7 
 
75.0 
 
18.7 
 
37.5 
 
87.5 
 
31.2 
 
100 
 
93.7 
 
56.2 
 
75.0 
 
 
56.2 
   
 
Table 10: Percentage of Correct Responses by Correct Answers Grouped by Age 
 
 
 
Table 11: Percentage of Correct Responses Answers Distributed by Gender 
1X 2  ( 3,N=259),7.97,p=.047 
Age  N  Q1 Q2 Q3 Q4 Q5 Q9 Q10 Q11 Q12 Q13 Q14 
18-20 162 93.2 79.6 15.4 43.8 85.1 37.6 95.6 90.7 79.0 88.8 44.4 
21-25 93 91.3 82.7   6.2 45.1 86.0 43.0 92.4 91.3 79.5 51.2 40.8 
26-29 3 100 100 33.3 33.3 66.6 66.6 66.6 100 100 100 100 
Gender  N  Q1 Q2 Q3 Q4¹ Q5 Q9 Q10 Q11 Q12 Q13 Q14 
Male 78 93.6 74.4 20.5 48.7 81.8 38.5 91.0 91.0 73.1 92.3 38.5 
Female 179 92.7 84.3 15.7 42.5 87.6 40.7 96.1 92.1 81.5 88.2 46.1 
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APPENDIX E 
Questionnaire 
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Sickle Cell Disease 
 
Age  __________ 
Gender     Male    Female 
Ethnicity      Caucasian       African American         Hispanic        Other  ________ 
Please select the one best answer. 
1.) What is sickle cell disease? 
A. Inherited blood disorder 
B. Infectious disease 
C. Sexually transmitted disease 
D. Fatal illness 
2.) Sickle cell disease evolved in which of the following continents? 
A. Africa 
B. Asia 
C. North America 
D. South America 
3.) In the United States, how many babies are born with sickle disease per year? 
A. 1,000 
B. 200,000 
C. 7,000,000,000 
D. 500,000 
4.) What is the estimated life expectancy of people living with sickle cell disease? 
A. 40  years 
B. 75  years 
C. 35  years 
D. 20  years 
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5.) What medical complications are caused by sickle cell disease? 
A. Stroke 
B. Lung tissue damage 
C. Pain episode 
D. All of the above 
9.)  What is the estimated number of people living with sickle cell disease in the United 
States? 
A.  2. 5 million  
              B. 1 million 
             C.  4  million 
             D. 6 million 
10.)  Is there a cure for sickle cell disease? 
A. Yes 
B. No 
11.)  What population is more at risk for developing sickle cell disease? 
 A. Caribbean Island 
               B. African  
               C.  Saudi Arabian 
               D.  Mediterranean 
12.) Sickle cell anemia is a medical condition where the red blood cells …. 
               A.  have an unusual shape 
               B.  have a higher than normal number  
               C.  are no longer produced by the body 
               D.  none of the above 
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13)  When is the appropriate time to test for sickle cell disease? 
              A. Newborn screening programs 
              B. Doctor check ups 
              C. At HIV testing 
              D.  At Sexually transmitted disease testing 
14.  What is the appropriate action for a person for child bearing age diagnosed with 
sickle cell disease? 
              A.  Preventive medicine 
              B.  Exercise 
              C.  Genetic counseling 
              D.  Vitamins  
 
         
 
 
           
 
 
 
 
